Need an on-the-go snack? Want to switch up the breakfast routine? Try making some of Chef Sachet’s kidney-friendly granola. As a mother and caregiver to a young boy suffering from FSGS, her recipes are tried and true for those following kidney conscious diets.

Granola Recipe

Prep Time: 5 min

Cook Time: 30 min

Yield: A LOT!

Ingredients:

• 6 cups oats
• 3 cups toasted shaved almonds
• 1 1/2 cups toasted sunflower seeds
• 1 cup unsweetened toasted coconut flakes
• 1 cup plumped raisins, dried cranberries
• 1 cup pure maple syrup
• 1 cup honey
• 1/2 cup coconut oil
• 2 tsp ground cinnamon (optional)

Instructions:

1. In a large bowl, toss oats with honey, syrup and oil.
2. Lay onto a non-stick baking sheet and toast in the over at 375 degrees for 20 min (or until oats are toasted and stiff). Be careful as to not over toast the oats as they will burn and turn bitter!
3. Let oats cool completely, then toss with other ingredients.
4. Store in a sealed cereal container or mason jar.

Important tips:

• Nuts (always use unsalted) provide a great source of protein for those trying to stay away from high phosphates in meat.
• Add some m&m’s and dried apricots and you got yourself a yummy trail mix!
• Add some yogurt, fresh fruit, and a drizzle of honey and you got yourself a delicious breakfast alternative!

Goldfinch Bio is a biotechnology company based in Cambridge, MA which focuses on advancing kidney precision medicine. Its mission is to deliver disease-modifying precision medicine that brings hope and renewed quality of life to people living with kidney diseases. We recently spoke with Goldfinch Bio’s Dr. Liron Walsh, Vice President Clinical and Translational Nephrology, who explains more about the company’s precision medicine approach, breaks down what podocytes are, and speaks more on its Phase 2 clinical research trial, TRACTION-2, which is currently enrolling patients.

What is precision medicine?

The causes of kidney disease are unique among groups of individuals. In diseases such as focal segmental glomerulosclerosis (FSGS), the causes of disease can vary from genetic to environmental. However, current treatments for FSGS are the same regardless of the cause.

With these “one-size-fits-all” approaches, some patients respond to treatment, while others do not. Many patients experience harmful side effects from these treatments with little to no benefits.

The goal of precision medicine is to develop treatments which are specifically designed to treat the underlying cause of an individual’s kidney disease. In this way, patients can receive the right medicine and avoid treatments which are not going to be helpful or may even be harmful.

Today, precision medicine is often used to treat cancer. By first understanding the genetic makeup of a patient’s tumor, a doctor can then choose the best medicine to specifically treat that patient’s cancer. This approach has greatly improved the lives of many people with cancer.

Precision medicine is now on the horizon for people with kidney diseases. Patients, nephrologists, and kidney researchers are working together to better understand the causes of kidney diseases. Through this deeper understanding, precision medicine will help develop treatments that target the specific causes of kidney diseases like FSGS and minimal change disease (MCD). Precision medicine holds promise to improve treatment outcomes and quality of life for many people living with kidney disease.

Goldfinch Bio and Precision Medicine

Goldfinch Bio is developing a novel experimental medicine, GFB-887, with the hope of preventing the progression of kidney disease in patients with FSGS, treatment-resistant MCD (TR-MCD), and diabetic nephropathy. While these kidney diseases may seem very different, they have something very important in common– very specialized cells of the kidneys called podocytes are damaged. GFB-887 is designed to specifically target these podocytes and prevent damage.

What are podocytes?

Podocytes are very specialized cells that wrap around the blood vessels of the kidneys. They form a network with other nearby podocytes to prevent the body from losing important proteins, such as albumin, while at the same time, filtering out waste. Normal functioning podocytes are very critical to our health.

When podocytes are damaged, gaps form in the barrier and important proteins are lost in the urine. This is commonly referred to as ‘spilling protein in the urine,’ and is an early sign of kidney disease. Patients with damaged podocytes experience swelling, weight gain, and fatigue. Unfortunately, damaged podocytes cannot heal, and they cannot be replaced by new, healthy podocytes. The kidney tries to repair the damage by creating a scar, much like the scar from a cut. Over time, more damage and more scarring will lead to kidney failure. By protecting the podocytes from being damaged in the first place and ensuring that the podocytes can function normally, it may be possible to prevent or delay kidney failure.

What makes the Goldfinch Bio team different than other pharmaceutical companies?

First, we are focused on advancing treatments for people with kidney diseases. Second, we are pioneering precision medicine for kidney diseases. While precision medicine is often used in cancer, and some rare genetic diseases as well, they are an entirely new area of drug research and development for kidney diseases. We are deeply committed to bringing innovative treatments to people with kidney diseases and working very closely with the patient community as partners.

Goldfinch Bio’s tagline is ‘Saving Kidneys, Ending Dialysis.’ How did you come up with this?

Our tagline– Saving Kidneys, Ending Dialysis–  is a shortened version of our vision, which is “We aspire to save kidneys and end dialysis.” We know that for many patients, kidney transplant and dialysis are the only treatment options. Unfortunately, kidney transplant may not be an option for many patients and is associated with significant long-term complications, and the experience of dialysis is very difficult. Through our precision medicine approach, we want to bring new, effective treatment solutions to patients so that we can give them hope and a renewed quality of life. We finalized our vision by hosting a focus group with people living with kidney disease to really understand what was important to them. A resounding theme emerged: these individuals expressed to us that they would give anything to avoid dialysis. And, from there, our new vision emerged.

Can you tell us more about your ongoing clinical trial?

The TRACTION-2 clinical research trial is evaluating our investigational precision medicine, GFB-887, for the potential treatment of FSGS, TR-MCD, and diabetic nephropathy. The purpose of the trial is to determine if GFB-887 is safe and may help people who have high levels of protein in their urine due to kidney diseases caused by podocyte injury. For more information on the trial, you can visit tractionclinicaltrial.com or at Kidney Health Gateway.

What are you most looking forward to at Goldfinch Bio?

We are very excited about the recent creation of our FSGS Patient Advisory Board.  We have created this board to foster a close working partnership with the patient community. For National Kidney Month, we held a virtual panel discussion with our board members. You can learn more about our Patient Advisory Board and watch the panel discussion here. We are very excited to continue to collaborate with this Board to ensure we have a patient-centric approach and mindset throughout our company.

To learn more about the TRACTION-2 clinical trial, click here. To see a full list of clinical research opportunities, and to find the trial best for you or your loved one, visit KidneyHealthGateway.com.

This article was developed in partnership with Goldfinch Bio, Inc.

 

Have you ever wondered what it might be like to walk in a kidney specialists’ shoes for a day?

Get a rare peek ‘behind the curtain’ and hear from actual nephrologists about their perspective on treating rare kidney patients, some of their daily challenges, and tips for making the most of your appointments.

Join us Sunday, May 16th from 12-4pm ET for the 2021 NephCure Patient Summit. During this FREE virtual gathering of patients from around the globe, you’ll hear about the latest in research and treatments and learn about your disease. You’ll also have the opportunity to directly ask our experts questions and participate in interactive community roundtables.

The “Day in the Life of a Nephrologist” panel will feature Drs. Jason Cobb, Michelle Rheault, and Suneel Udani. The Patient Summit will also offer you the chance to hear from other NephCure specialists, NephCure staff, and regional volunteer leaders.

Meet the Panelists:

Dr. Jason Cobb is an assistant professor of medicine in the Emory University Division of Renal Medicine. Dr. Cobb is a graduate of Morehouse College with a BS in biology. He holds a medical degree from Emory University School of Medicine and completed his internal medicine residency and nephrology fellowship at Emory University. He is board-certified in internal medicine and nephrology. He sees patients in nephrology clinic at Emory University Hospital Midtown in the Medical Office Tower seeing patients with nephrology complaints such as chronic kidney disease due to diabetes, hypertension, vascular disease, and glomerulonephritis. Also, Dr. Cobb takes care of hemodialysis patients at Emory Dialysis Greenbriar and Emory Dialysis Northside, and home dialysis patients at Emory Dialysis Northside. He also rounds on inpatient services at Emory University Hospital Midtown and Emory University Hospital. Research and teaching interests include quality improvement and nephrology fellow clinic at Grady Memorial Hospital.

Dr. Michelle Rheault is a board certified pediatric nephrologist and Associate Professor of Pediatrics. She completed her Pediatric Nephrology fellowship at the University of Minnesota in 2006 followed by a research fellowship at Mount Sinai School of Medicine in New York City. She joined the faculty at the University of Minnesota in 2008 and is currently the Director of the Division of Pediatric Nephrology and Medical Director of the Pediatric Dialysis unit. She is on the steering committee of the Pediatric Nephrology Research Consortium, a clinical research network that aims to facilitate collaboration in pediatric nephrology. Her clinical and research interests include Alport syndrome and other genetic kidney diseases, pediatric glomerular disease, and pediatric end stage kidney disease.

Dr. Suneel Udani is a native of Chicago’s western suburbs.  He joined Advanced Renal Care in July 2011. He completed his undergraduate, Master’s in Public Health, and medical school degrees at Northwestern University and went on to do his Internal Medicine training at the University of Chicago and the University of Pittsburgh. He served as a Chief Medical Resident at Cook County Hospital prior to returning to the University of Chicago for his fellowship in Nephrology. Dr. Udani is the author of multiple peer-reviewed journal articles and has presented his research at national conferences and is the author of multiple text book chapters on diagnosis and management of kidney disease. His focus is on glomerular disease and heart-kidney interactions. He is also a clinical investigator for community-based renal research program and a dedicated educator and advocate for patients with kidney disease.

To learn more about the 2021 NephCure Patient Summit, including a full list of speakers, and full event agenda, click here. 

NephCure’s Nurse Kristen Hood and Kylie Winkler discuss Travere’s Therapeutics achievement of interim proteinuria endpoint in the ongoing Phase 3 DUPLEX study of Sparsentan in Focal Segmental Glomerulosclerosis (FSGS).

Learn more about the trial currently underway, why this is such a crucial step for patients with rare kidney diseases, and what potential treatments this could lead to in just a few short years! Read the full press release here. 

A new educational resource is available for FSGS patients worldwide. We are proud to collaborate with WebMD/Medscape to make focal segmental glomerulosclerosis (FSGS) available as a program on the WebMD website. You can check out the brand-new information here.

Within this program, you can test your FSGS knowledge, learn more about the causes of the rare protein-spilling kidney diseases, and find out about the treatment options that are available—including a deeper dive into clinical trials.

This resource also includes a video from NephCure Board Member and NephCure Specialist, Dr. Kirk Campbell. He shares his expertise on the treatment options for those suffering from FSGS and breaks down the importance of enrolling in a clinical trial.

We encourage you to take a look at this program on WebMD and share with family and friends to help shed light on you or your loved one’s medical condition.

This program was supported by an independent educational grant from Travere Therapeutics. To learn even more about FSGS and treatment options, click here.

Written by Linda Lujan.

This year, my confidence and health were greatly challenged as I faced the reality of learning that I developed a serious, potentially life-threatening disease and tested positive for COVID-19 in the same ER visit. Though I did not receive my diagnosis of Minimal Change Disease until June 24, 2020, my journey started many months prior.

That’s where I’ll start my story of “Welcome to 2020.”

After a flight to Texas during the week of Christmas 2019, I noticed my ankles were swollen. I thought it was due to the long flight, and I tried to relieve the swelling by elevating my legs and wearing compression socks during my weeklong stay, which helped relieve the swelling to some degree. Upon my return to Oregon, the swelling eventually resolved.

As 2020 began, I was off to a great start. I was healthy and training for a half-marathon, my nutrition was on point, I was not taking any medication, and I had no underlying health conditions.

Things began to change just a few weeks later.

From mid-January through early March, I started gaining weight for no apparent reason. I gained a pound or so a week and couldn’t figure out why. In late February, I noticed that my legs were swollen. I started paying more attention, and though the swelling wasn’t improving, instead of thinking I had a medical issue, I thought it was related to my exercise routine. At this point, I was cycling 100+ miles every week!

In mid to late March, my weight was still climbing a pound at a time, and the swelling in my legs was still prevalent. I saw my family doctor, who also thought it was related to my exercise and prescribed a diuretic. A week later there was no change, so I returned to the doctor. After seeing my albumin level in my lab results, he asked me to increase my protein intake by 20%. Within a week the swelling in my legs mostly resolved, but then my abdomen started swelling.

On March 30, after a long weekend of considerable discomfort in my stomach from extreme swelling and now severe fatigue, I once again went to see my doctor. He wanted a CT scan of my belly, but because insurance was going to take three to five days to approve it, he sent me to the emergency room.

There, a scan was taken of my abdomen and lungs. The ER doctor indicated that he believed I had Nephrotic Syndrome and had consulted with a nephrologist in Portland who asked that I be transferred to a hospital there.

But there was one problem! The scan of my lungs revealed what was described as glass shards, which the doctor believed was an indicator I was positive for COVID-19. The doctor in Portland began working on getting me into a hospital — but special conditions were needed for my admission because he believed I was positive for COVID-19.

I was transported by ambulance to Meridian Park Hospital in Portland. Upon arrival, I was taken straight to a room, bypassing what I assume would be normal procedure for a transfer. It felt a bit chaotic and I was definitely scared. My husband wasn’t allowed to be with me and would not be allowed to come see me.

I was in a lot of pain, and I was processing a lot of information: what it meant to have COVID, and what in the heck Nephrotic Syndrome even was. It was a surreal and terrifying experience.

After getting settled into a room, I was put on a diuretic through IV. By the next day, I was feeling much better with respect to the pressure in my abdomen. That morning, the doctor confirmed my Nephrotic Syndrome diagnosis.

He said I needed a kidney biopsy to determine what specific kidney disease I had, and he also wanted an ultrasound; however, the hospital declined both orders due to coronavirus restrictions. A 24-hour urine catch was ordered, which revealed a high level of protein. The COVID-19 test came back that day as well — with a positive result.

I was in the hospital for four days in a particular area that was set aside for COVID patients. At that time, there were eight patients suspected of having the virus, but I was the only confirmed positive case. What should have been a routine hospital stay (if there is such a thing) was complicated by my COVID diagnosis. I later learned from my doctor that, because he believed I had contracted COVID before it was confirmed, he fought for extreme measures for my care in addition to the coronavirus protocol the hospital already had in place.

The safety protocols he asked to be implemented for my care included only one hospital doctor assigned to me, one nurse per shift allowed in my room, and meals delivered only as far as the door. Everything that came in my room was disposable, and nothing left my room. The extreme end of this caution was that during the 24-hour urine catch, I was asked to measure the urine, transfer it to a larger bag on ice, and document the measurements. I was way too sick to be managing such a task.

Upon discharge from the hospital, my nephrologist informed me that I would not be able to get the biopsy until I tested negative for COVID, and, once he knew my diagnosis, treatment would not begin until I had a second consecutive negative test. Unfortunately, over the next seven weeks, I continued to test positive.

The time period between my discharge from the hospital with a general diagnosis of Nephrotic Syndrome and starting treatment for it was about 12 weeks. It was a long 12 weeks!

Emotionally, I was scared to death because I didn’t know what was wrong with me. The only thing I could do during that time was to research Nephrotic Syndrome — because that’s all I knew was wrong with me.

It was very scary to not know my specific kidney disease diagnosis. Every positive COVID test added another level of disappointment, as it further delayed a diagnosis and treatment.

This time period was stressful and emotionally challenging. I faced the reality that I had a kidney disease, but that I didn’t yet know which disease, how much damage (if any) my kidneys had suffered, and what long-term effects could result. I was concerned things would get worse as I continued to wait for a negative COVID-19 test.

I finally tested negative and was able to get my biopsy in early June. On June 24, I received a diagnosis of Minimal Change Disease and started treatment of 60 mg of prednisone. My first lab results four weeks from that date revealed I was in remission, so I started to quickly taper off the prednisone.

After I was released from the hospital, the nurse at the kidney center kept telling me that my doctor was fascinated by my case. I asked the PA about this, and he told me the doctor believed I had contracted COVID in late fall 2019 and that it had started attacking my kidneys when the first swelling presented in late December — causing my Minimal Change Disease.

Furthermore, the doctor believed I was one of the first cases of such a diagnosis to be caused by COVID-19, and therefore a case for medical journals. At my diagnosis appointment, he told me he’d discussed my case with peers worldwide, and they were all of the belief that I was the first case in the U.S. to have had the coronavirus lead to Nephrotic Syndrome without having any underlying conditions. At the time of the kidney biopsy, my doctor asked the pathologist for an analysis for COVID to give insight to this theory, but the pathologist could not confirm it.

My doctor told me that if he was right about COVID-19 causing my MCD, I would be in remission quickly, and that I would most likely have little chance of relapse. He was right. I’ve been in remission since the four-week mark, and I’m praying for no relapse.

During the same appointment, he told me he was participating in a COVID/kidney case study and that he was presenting my case for it; that case study has since been published.

Throughout this whirlwind year, NephCure has been amazing. When I received the initial diagnosis, I researched Nephrotic Syndrome a million and one ways. I kept changing my search words and finally came across NephCure’s Facebook group.

I posted that I had a Nephrotic Syndrome diagnosis but had to wait on a biopsy because of COVID-19; a patient advocate for NephCure replied to my post and we talked on the phone a few days later. She gave me so much information and put me in contact with Kelly Helm, NephCure’s assistant director of patient advocacy.

I then learned about the bi-monthly peer-to-peer video calls and started participating in them — I learned so much from the other participants on those calls, as well as from Nurse Kristen! One participant reached out to me via private message and gave me so much helpful information.

Kelly kept in contact with me, and was also very supportive and responsive to my questions and/or concerns. I truly appreciated the support group and Facebook page, and the opportunity NephCure gave me to hear from people who shared similar challenges.

Today, I am healthy, medicine-free, and have been back to my regular exercise routine since early September! I pray every day I stay in remission.